UTHR · CIK 1082554
What United Therapeutics Corporation told the SEC could break it.
United Therapeutics' disclosures concentrate at the two ends of its business — who sells its drugs and who makes them. Substantially all of its U.S. revenue flows through just two specialty-pharmacy distributors, one at 51% and one at 36% of total revenue (about 87% combined), so the loss of, or order-timing shifts at, Accredo or CVS Specialty would swing results materially. On the supply side it leans on third parties, sometimes exclusively, for critical manufacturing — Lilly for Adcirca, MannKind for Tyvaso DPI, Sanner GmbH as the sole maker of Remodulin MS-3 cartridges, and sole-source suppliers for ralinepag — plus second- and third-tier raw-material suppliers in China, India and Taiwan it has limited visibility into. Wrapping both is regulatory pressure: FDA approval and supply constraints and IRA drug-pricing reforms, alongside tariffs on its sub-tier supply chain.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- two U.S. specialty-pharmacy distributors (Accredo, CVS Specialty)high
United Therapeutics derives substantially all U.S. treprostinil revenue from two distributors — one at 51% and one at 36% of total revenue (~87% combined) — so order-timing or loss of either (Accredo or CVS Specialty) materially swings revenue.
“We recorded revenue from two distributors in the United States that exceeded ten percent of total revenues. ... Distributor 1 51 % 51 % 51 % Distributor 2 36 % 35 % 34 %”
SEC filing →As of 2026
Sole-source dependency
- exclusive/sole-source manufacturers and device suppliershigh
UTHR relies entirely on third parties (sometimes exclusively) for critical manufacturing — Lilly for Adcirca, MannKind for Tyvaso DPI, Sanner GmbH for Remodulin MS-3 cartridges, third parties for pumps/nebulizers, and sole-source suppliers for ralinepag.
“We also rely on various sole-source suppliers for manufacturing activities related to ralinepag. ... Finally, we rely entirely on Sanner GmbH to manufacture cartridges that were cleared by the FDA for use with the MS-3 pump to administer Remodulin.”
SEC filing →As of 2026
Regulatory & policy
- FDA drug regulation, IRA drug pricing and Unituxin supplymedium
UTHR faces FDA approval/manufacturing-specification risk (e.g., 2025 Unituxin supply limitations to Japan and shortage risk from its short shelf life), plus IRA and other drug-pricing reforms and drug-importation pathways pressuring payment.
“The IRA and other healthcare reform measures that may be adopted in the future may result in additional downward pressure on the payment that we receive for any approved product, and may adversely impact our business.”
Supplier concentration
- sub-tier raw-material suppliers in China/India/Taiwan and tariffsmedium
Suppliers in China, India and Taiwan support UTHR's second- and third-tier supply of raw materials/consumables (with limited visibility into those chains); trade disputes and Trump-administration tariffs raise input-cost and disruption risk despite US-based API/finished manufacturing.
“Suppliers based in China, India, and Taiwan play a role in our supply chain to support our second- and third-tier suppliers. Political unrest or trade disputes involving China, India, Taiwan, or other countries in our supply chain could impact our ability and the ability of our third-party manufacturers to source raw materials and consumables.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Accredo (Cigna/Express Scripts specialty pharmacy)
“In the United States, we derive substantially all our treprostinil-based revenues from sales to two distributors, Accredo and CVS Specialty. ... Distributor 1 51 % 51 % 51 % Distributor 2 36 % 35 % 34 %”
Cited →CVS Specialty (CVS Health)
“In the United States, we derive substantially all our treprostinil-based revenues from sales to two distributors, Accredo and CVS Specialty. ... Distributor 1 51 % 51 % 51 % Distributor 2 36 % 35 % 34 %”
Cited →
Its suppliers
“If MannKind is unable to manufacture Tyvaso DPI in sufficient quantities for us for any reason, our commercial sales of Tyvaso DPI could be materially and adversely impacted.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch